Basilea Pharmaceutica AG BSLN
Dividend Summary
The previous Basilea Pharmaceutica AG dividend was 500c and it went ex over 11 years ago and it was paid over 11 years ago.
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | Paid | – |
| Type | Special | – |
| Per share | 500c | – |
| Declaration date | 06 Apr 2013 (Sat) | – |
| Ex-div date | 11 Apr 2013 (Thu) | – |
| Pay date | 21 Jun 2013 (Fri) | – |
Enter the number of Basilea Pharmaceutica AG shares you hold and we'll calculate your dividend payments:
Sign up for Basilea Pharmaceutica AG and we'll email you the dividend information when they declare.
Add Basilea Pharmaceutica AG to receive free notifications when they declare their dividends.
Your account is set up to receive Basilea Pharmaceutica AG notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| Paid | Special | 06 Apr 2013 | 11 Apr 2013 | 21 Jun 2013 | CHF | — | 500c |
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0c | — |
| 2007 | 0.0c | 0% |
| 2008 | 0.0c | 0% |
| 2009 | 0.0c | 0% |
| 2010 | 0.0c | 0% |
| 2011 | 0.0c | 0% |
| 2012 | 0.0c | 0% |
| 2013 | 0.0c | 0% |
| 2014 | 0.0c | 0% |
| 2015 | 0.0c | 0% |
| 2016 | 0.0c | 0% |
| 2017 | 0.0c | 0% |
| 2018 | 0.0c | 0% |
| 2019 | 0.0c | 0% |
| 2020 | 0.0c | 0% |
| 2021 | 0.0c | 0% |
| 2022 | 0.0c | 0% |
| 2023 | 0.0c | 0% |
| 2024 | Sign Up Required | |
Basilea Pharmaceutica AG Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 17 October 2024
- 52 Week Low
- 0.0% on 17 October 2024
- Next Ex-Div-Date Countdown
- Sign Up Required
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- Switzerland
- Share Price
- Fr.41.50 (yesterday's closing price)
- Shares in Issue
- 13 million
- Market Cap
- Fr.547mn
- 0
- Market Indices
- none
